Drugs in development for toxoplasmosis

Advances, challenges, and current status

P. Holland Alday, Joseph Doggett

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis.

Original languageEnglish (US)
Pages (from-to)273-293
Number of pages21
JournalDrug Design, Development and Therapy
Volume11
DOIs
StatePublished - Jan 25 2017

Fingerprint

Toxoplasmosis
Pharmaceutical Preparations
Toxoplasma
Cysts
Eye Diseases
Poisons
Drug Design
Brain Diseases
Safety
Pregnancy
Brain
Therapeutics

Keywords

  • Apicomplexa
  • Experimental medicine
  • Mechanism of action
  • Preclinical medicine
  • Therapeutics
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Drugs in development for toxoplasmosis : Advances, challenges, and current status. / Alday, P. Holland; Doggett, Joseph.

In: Drug Design, Development and Therapy, Vol. 11, 25.01.2017, p. 273-293.

Research output: Contribution to journalReview article

@article{8c90fc4f782e4b92b676073d0154efc8,
title = "Drugs in development for toxoplasmosis: Advances, challenges, and current status",
abstract = "Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis.",
keywords = "Apicomplexa, Experimental medicine, Mechanism of action, Preclinical medicine, Therapeutics, Toxoplasma gondii",
author = "Alday, {P. Holland} and Joseph Doggett",
year = "2017",
month = "1",
day = "25",
doi = "10.2147/DDDT.S60973",
language = "English (US)",
volume = "11",
pages = "273--293",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Drugs in development for toxoplasmosis

T2 - Advances, challenges, and current status

AU - Alday, P. Holland

AU - Doggett, Joseph

PY - 2017/1/25

Y1 - 2017/1/25

N2 - Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis.

AB - Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis.

KW - Apicomplexa

KW - Experimental medicine

KW - Mechanism of action

KW - Preclinical medicine

KW - Therapeutics

KW - Toxoplasma gondii

UR - http://www.scopus.com/inward/record.url?scp=85011654043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011654043&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S60973

DO - 10.2147/DDDT.S60973

M3 - Review article

VL - 11

SP - 273

EP - 293

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -